Figure 2.
Survival curves for pediatric patients with KMT2A-rearranged AML, stratified by fusion-based group. Kaplan-Meier estimates of (A) EFS, (B) CIR, and (C) OS of KMT2A fusion-based groups. KMT2A::MLLT3 refers to t(9;11)(p22;q23) (n = 544), KMT2A::MLLT10 to t(10;11)(p12;q23) (n = 218), KMT2A::AFDN to t(6;11)(q27;q23) (n = 92), KMT2A::ELL to t(11;19)(q23;p13.1) (n = 75), KMT2A::MLLT1 to t(11;19)(q23;p13.3) (n = 56), KMT2A::MLLT11 to t(1;11)(q21;q23) (n = 28), KMT2A::ABI1 to t(10;11)(p11.2;q23) (n = 24), 19p13 to t(11;19)(q23;p13) without ascertained subband (n = 23), KMT2A::SEPT6 to t(X;11)(q24;q23) (n = 22), 17q21 to t(11;17)(q23;q21) (n = 13), KMT2A::EPS15 to t(1;11)(p32;q23) (n = 13), KMT2A::AFF1 to t(4;11)(q21;q23) (n = 12), and 17q12 to t(11;17)(q23;q12) (n = 10).

Survival curves for pediatric patients with KMT2A-rearranged AML, stratified by fusion-based group. Kaplan-Meier estimates of (A) EFS, (B) CIR, and (C) OS of KMT2A fusion-based groups. KMT2A::MLLT3 refers to t(9;11)(p22;q23) (n = 544), KMT2A::MLLT10 to t(10;11)(p12;q23) (n = 218), KMT2A::AFDN to t(6;11)(q27;q23) (n = 92), KMT2A::ELL to t(11;19)(q23;p13.1) (n = 75), KMT2A::MLLT1 to t(11;19)(q23;p13.3) (n = 56), KMT2A::MLLT11 to t(1;11)(q21;q23) (n = 28), KMT2A::ABI1 to t(10;11)(p11.2;q23) (n = 24), 19p13 to t(11;19)(q23;p13) without ascertained subband (n = 23), KMT2A::SEPT6 to t(X;11)(q24;q23) (n = 22), 17q21 to t(11;17)(q23;q21) (n = 13), KMT2A::EPS15 to t(1;11)(p32;q23) (n = 13), KMT2A::AFF1 to t(4;11)(q21;q23) (n = 12), and 17q12 to t(11;17)(q23;q12) (n = 10).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal